US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Teva Pharmaceutical Industries Ltd

< Previous 1 2 3 4 Next >
News headline image
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers ALVO TEVA
News headline image
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Releases Q1 2025 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers SNY TEVA
News headline image
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers ALVO TEVA
News headline image
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva to Present at the Jefferies London Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
News headline image
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
< Previous 1 2 3 4 Next >